



26 July 2019

ASX ANNOUNCEMENT

CHANGE IN EXERCISE PRICE OF OPTIONS

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company**), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announced a 1-for-3 fully underwritten, pro-rata, non-renounceable entitlement offer of approximately 126.6 million shares in the Company to raise approximately \$13.9 million, on 27 June 2019 (**Entitlement Offer**).

In accordance with the rules of the Company's 2014 Employee Incentive Plan approved by the board on 18 September 2014 (**Plan**) and ASX Listing Rules 3.11.2 and 6.22, the Company advises that, as a consequence of the Entitlement Offer, the exercise price of options over unissued shares in the Company outstanding under the Plan will change on 2 August 2019 as set out in the table below.

Options	Current exercise price (US\$)	New exercise price (US\$)
132,000	0.6900	0.6883
37,771	0.8700	0.8683
5,345,000	0.6900	0.6883
1,446,500	0.8700	0.8683
200,000	1.0300	1.0283
100,000	1.0500	1.0483
375,000	0.8900	0.8883
200,000	1.3200	1.3183
821,000	1.6600	1.6583
590,500	1.4700	1.4683
335,000	1.4600	1.4583
872,000	1.4600	1.4583
120,000	0.7400	0.7383
262,500	0.6400	0.6383
5,575,000	0.8150	0.8133
306,000	0.6800	0.6783
578,000	0.5200	0.5183
70,000	0.2300	0.2283
75,000	0.2300	0.2283
100,000	0.1350	0.1333
533,000	0.1350	0.1333

Contact details

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.